Breaking from tradition. Ignite the path to a cure.

David Deems


Recent Posts

Drug response reports: a foundation for the accelerated development of new cancer treatments.

[fa icon='calendar'] Jun 3, 2021 8:25:05 AM / by David Deems posted in Drug Response Data

[fa icon="comment"] 0 Comments

The purpose of Cellaria’s in vitro cancer cell models is to accelerate clinical studies by facilitating the study of disease within specific and unique patient biology. We use our expertise in cell line growth, stabilization, and characterization to provide tools that answer directly to the requirements of those at the cutting edge of oncology research. While the models are our core product, we think hard about the information provided with them to ensure that researchers choose the most suitable model and use it productively from the get-go. 

Read More [fa icon="long-arrow-right"]

An Interview with Chief Technology Officer Dima Shvartsman, Ph.D

[fa icon='calendar'] May 27, 2021 10:52:26 AM / by David Deems posted in Insider , Interview

[fa icon="comment"] 0 Comments

We sat down with CTO Dima Shvartsman, Ph.D to speak about his role within the company and the exciting potential for human health research using Cellaria's cell lines and cell models. 

Read More [fa icon="long-arrow-right"]

Cellaria Inc. launches new cell lines to support the development of personalized therapies for lung cancer

[fa icon='calendar'] May 27, 2021 8:59:55 AM / by David Deems posted in Press Release , Lung Cancer Cell Models

[fa icon="comment"] 0 Comments

Offering researchers a diverse cohort of patient specific models to accelerate drug development.

Read More [fa icon="long-arrow-right"]

New Lung Cancer Cell Lines for a Diverse Patient Cohort

[fa icon='calendar'] May 25, 2021 1:00:00 PM / by David Deems posted in Lung Cancer Cell Models , Drug Response Data

[fa icon="comment"] 0 Comments

A diverse patient cohort for non-small cell lung cancer

Read More [fa icon="long-arrow-right"]

An Interview with Sales Development Executive  Assem Nurlanbekova

[fa icon='calendar'] Apr 22, 2021 2:50:55 PM / by David Deems posted in Insider , Interview

[fa icon="comment"] 0 Comments

 

Read More [fa icon="long-arrow-right"]

Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce  Collaboration to Design and Qualify Biomarker-Specific Small  Protein Therapeutics

[fa icon='calendar'] Apr 22, 2021 8:06:39 AM / by David Deems posted in Vyant Bio, Inc , drug discovery , Ordaōs Bio

[fa icon="comment"] 0 Comments

New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials

 

Read More [fa icon="long-arrow-right"]

New research demonstrates value of patient-specific cancer models in studies of metastasis and drug resistance

[fa icon='calendar'] Apr 15, 2021 1:26:57 PM / by David Deems posted in Drug resistance , metastasis , Press Release

[fa icon="comment"] 0 Comments

Cellaria scientists to present latest studies at

AACR 2021

Read More [fa icon="long-arrow-right"]

An Interview with Research Associate Maria Ivanova

[fa icon='calendar'] Mar 24, 2021 4:25:36 PM / by David Deems posted in Insider , Interview

[fa icon="comment"] 0 Comments

 

Read More [fa icon="long-arrow-right"]

Leading innovators collaborate to provide new, patient representative cell culture solutions for smarter in vitro research.

[fa icon='calendar'] Mar 16, 2021 3:44:50 PM / by David Deems posted in Insider , BioLamina

[fa icon="comment"] 0 Comments

Read More [fa icon="long-arrow-right"]

Partnership with Northeastern University to advance new photomedicine therapies for key cancers

[fa icon='calendar'] Jan 4, 2021 12:45:21 PM / by David Deems posted in Pancreatic , Bryan Spring

[fa icon="comment"] 0 Comments

We are pleased to announce a grant collaboration with Dr. Bryan Spring, of Northeastern University. Recently, we sat down with Dr. Spring to understand the value sees with Cellaria cell models when compared to conventional cell lines for pancreatic and ovarian cancer. The ultimate goal of his lab is to reduce cancer recurrence and mortality by establishing new approaches for personalized medicine that address tumor heterogeneity, drug-resistance and molecular mechanisms of treatment.

Read More [fa icon="long-arrow-right"]